Mumbai, Sep 23: Pharma major Lupin announced the launch of Divalproex Sodium Extended-Release (ER) Tablets USP, 250 mg and 500 mg, which had got an approval from the United States Food and Drug Administration (USFDA) earlier.
The product will be manufactured at Lupin’s Nagpur facility in India.
Divalproex Sodium ER Tablets USP, 250 mg and 500 mg, is the generic equivalent of Depakote? ExtendedRelease (ER) Tablets, 250 mg and 500 mg, of AbbVie Inc, indicated for: Acute treatment of manic or mixed episodes associated with bipolar disorder, with or without psychotic features Prophylaxis of migraine headaches
It is also indicated for Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures Divalproex Sodium Extended-Release (ER) Tablets USP (RLD: Depakote? ER) had annual sales of approximately USD 130 million in the US (IQVIA MAT July 2020). (UNI)
Follow our WhatsApp channel
